This company has been acquired
Sigilon Therapeutics Future Growth
Future criteria checks 0/6
Sigilon Therapeutics's earnings is forecasted to decline at -9.5% per annum while its annual revenue is expected to grow at 3.5% per year. EPS is expected to grow by 5.1%. Return on equity is forecast to be -159.8% in 3 years.
Key information
-9.5%
Earnings growth rate
5.1%
EPS growth rate
| Biotechs earnings growth | 20.7% |
| Revenue growth rate | 3.5% |
| Future return on equity | -159.8% |
| Analyst coverage | Low |
| Last updated | 11 Aug 2023 |
Recent future growth updates
Recent updates
Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet
Apr 17
Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M
Aug 04Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer
Jun 14What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?
Mar 04Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.
Dec 17Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 16 | -38 | N/A | N/A | 2 |
| 12/31/2024 | 16 | -35 | N/A | N/A | 2 |
| 12/31/2023 | 16 | -32 | N/A | N/A | 2 |
| 6/30/2023 | 18 | -30 | -33 | -33 | N/A |
| 3/31/2023 | 15 | -37 | -44 | -43 | N/A |
| 12/31/2022 | 13 | -44 | -52 | -51 | N/A |
| 9/30/2022 | 12 | -55 | -62 | -62 | N/A |
| 6/30/2022 | 10 | -66 | -75 | -74 | N/A |
| 3/31/2022 | 10 | -72 | -77 | -75 | N/A |
| 12/31/2021 | 10 | -77 | -80 | -78 | N/A |
| 9/30/2021 | 11 | -75 | -80 | -78 | N/A |
| 6/30/2021 | 14 | -68 | -71 | -69 | N/A |
| 3/31/2021 | 13 | -61 | -70 | -69 | N/A |
| 12/31/2020 | 13 | -55 | -63 | -62 | N/A |
| 9/30/2020 | 13 | -52 | -59 | -58 | N/A |
| 6/30/2020 | 13 | -51 | -59 | -59 | N/A |
| 3/31/2020 | 14 | -47 | -55 | -54 | N/A |
| 12/31/2019 | 14 | -44 | -51 | -50 | N/A |
| 12/31/2018 | 5 | -26 | 37 | 38 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SGTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SGTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SGTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SGTX's revenue (3.5% per year) is forecast to grow slower than the US market (7.7% per year).
High Growth Revenue: SGTX's revenue (3.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SGTX is forecast to be unprofitable in 3 years.